MET

Across TCGA pan-cancer cohorts, MET mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated MET data layer compared with 25 for mass-spec protein and 10 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MET mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MET expression acts as an unfavorable survival marker, although some lineages such as COAD and HNSC show a favorable association.

PDAC, COAD, and HNSC are the cancer types where MET mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.235	0.563	<.001	56	view →
COAD	DFS	Median	All	1.000	0.931	.028	30	view →
HNSC	DFS	Tertile	IV	0.836	0.521	.007	7	view →
CCRCC	OS	Quartile	All	0.742	0.962	.004	7	view →
LUAD	DFS	Quartile	All	0.780	0.470	.039	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

MET–PDAC (DFS)

Open the PDAC breakdown →